DAFTAR PUSTAKA


25. Adam JR, Angelotta C, Bennet CR. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?. J of Clin Oncology 2006; 24: 2975-7


